Synthetic analog · 33 amino acids · 3,752.1 Da

Teduglutide studies and research data

PepBank has 54 teduglutide studies with results. All of them gave teduglutide, with 362 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 362 results and 256 papers. Newer studies from Europe PMC

Results in people

239

66% of 362 results

Results in animals

27% of 362 results

Results in lab cells

7% of 362 results

From computer models

0% of 362 results

The molecule

Teduglutide identity

Identifiers, parent molecule, targets and development stage, from curated data.

Teduglutide is a 33-residue GLP-2 analog. It replaces Ala2 with Gly and activates GLP-2 receptors. Its approved use concerns short bowel syndrome requiring parenteral support.

Kind: Synthetic analog · 33 residues
Identifiers: ChEMBLCHEMBL2104987 (opens in a new tab)PubChem CID16139605 (opens in a new tab)UNII7M19191IKG (opens in a new tab)DrugBankDB08900 (opens in a new tab)CAS197922-42-2
Parent: Analog of Glucagon-like peptide 2Teduglutide replaces alanine with glycine at position 2 of mature human GLP-2. UniProt P01275 contains GLP-2 at precursor residues 146-178. This is a GLP-2 analog relationship, not identity with mature glucagon. No existing glucagon slug is assigned as the parent.
Development: Approved in the US and EU (Gattex)An approved medicinal product exists. Availability and other indications can differ. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Glucagon-like peptide 2 receptorGLP2RO95838 (opens in a new tab)	Agonist	Official prescribing information, mechanism of actionSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

33 amino acids

H-

HGDGSFSDEM

NTILDNLAAR

DFINWLIQTK

ITD

-OH

Parent: Glucagon-like peptide 2

No sequence is listed for the parent, so no alignment is shown.Teduglutide replaces alanine with glycine at position 2 of mature human GLP-2. UniProt P01275 contains GLP-2 at precursor residues 146-178. This is a GLP-2 analog relationship, not identity with mature glucagon. No existing glucagon slug is assigned as the parent.

Properties

From identity sources

Formula: C₁₆₄H₂₅₂N₄₄O₅₅S
Molecular weight: 3,752.1 g/mol
Monoisotopic mass: 3,749.7995 Da

GSRS UNII 7M19191IKG(opens in a new tab)retrieved 2026-10-27
PubChem CID 16139605(opens in a new tab)retrieved 2026-10-27
Curated Gattex US label(opens in a new tab)retrieved 2026-10-27

Calculated from the sequence

pKa set

Average mass: 3,752.13 Da; Sum of ExPASy residue masses + water · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 3,749.7995 Da; Sum of ExPASy residue masses + water · ExPASy FindMod
Isoelectric point (pI): 4.01; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: −3.95; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −0.348; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 5,500 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
Instability index: 5.56; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; 40 or below: classed as stable (ExPASy).
Aliphatic index: 88.8; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 1.97 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): 0.594; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984
pI with each pKa set: EMBOSS 4.01Bjellqvist (ExPASy) 4.30IPC peptide 3.96IPC protein 3.97

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 4.01 · Net charge at pH 7.4: −3.95

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.

Show as table

pH	Net charge
0	4.00
1	3.99
2	3.91
3	3.17
4	0.05
5	−2.51
6	−3.19
7	−3.78
8	−4.17
9	−4.73
10	−5.10
11	−5.64
12	−6.18
13	−6.75
14	−6.97

Composition

Hydrophobic30% (10)A I L M
Aromatic9% (3)F W
Positive9% (3)H K R
Negative18% (6)D E
Polar27% (9)N Q S T
Special6% (2)G

33 residues. Each residue counts in one class; F and W count as aromatic.

A Ala2 · 6%

I Ile4 · 12%

L Leu3 · 9%

M Met1 · 3%

V Val0 · 0%

F Phe2 · 6%

W Trp1 · 3%

Y Tyr0 · 0%

H His1 · 3%

K Lys1 · 3%

R Arg1 · 3%

D Asp5 · 15%

E Glu1 · 3%

N Asn3 · 9%

Q Gln1 · 3%

S Ser2 · 6%

T Thr3 · 9%

C Cys0 · 0%

G Gly2 · 6%

P Pro0 · 0%

3D structure

PredictedAlphaFold DB · P01275

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

Teduglutide has 33 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.

SMILES fromPubChem CID 16139605(opens in a new tab)

CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC5=CN=CN5)N

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.085
μH, best 11-residue window: 0.594
Arrow direction: 170°
Residues: 33 · 2 rings of 18

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	H	0°	-0.40
2	G	100°	0.48
3	D	200°	-0.90
4	G	300°	0.48
5	S	40°	-0.18
6	F	140°	1.19
7	S	240°	-0.18
8	D	340°	-0.90
9	E	80°	-0.74
10	M	180°	0.64
11	N	280°	-0.78
12	T	20°	-0.05
13	I	120°	1.38
14	L	220°	1.06
15	D	320°	-0.90
16	N	60°	-0.78
17	L	160°	1.06
18	A	260°	0.62
19	A	0°	0.62
20	R	100°	-2.53
21	D	200°	-0.90
22	F	300°	1.19
23	I	40°	1.38
24	N	140°	-0.78
25	W	240°	0.81
26	L	340°	1.06
27	I	80°	1.38
28	Q	180°	-0.85
29	T	280°	-0.05
30	K	20°	-1.50
31	I	120°	1.38
32	T	220°	-0.05
33	D	320°	-0.90

Results by area

Teduglutide results by year and outcome

Counts are exact and come from studies that gave the peptide.

Teduglutide has 256 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

Studies by year

54 of 256 studies have results (21%), published 2004 to 2026. Top row: every study. Bottom row: studies with results about Teduglutide, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies256 in all, 2004 to 2027

Studies with results54 in all, 2004 to 2026

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Teduglutide studies on survival and serious illness

87 results · people 87 · animals 0 · lab 0

Top 5 of 87 results

In patients with short bowel syndrome, teduglutide 0.05 mg/kg/day improved graded response versus placebo.Gut, 2011
In healthy subjects, no deaths occurred during the study, including among teduglutide recipients.BMC gastroenterology, 2014
In the overall SBS-IF population, the response-rate difference favored teduglutide over placebo.Therapeutics and clinical risk management, 2018
In children under 10 kg with short bowel syndrome, no adverse events during teduglutide treatment led to death.Pediatrics international, 2026
In children with SBS-IF, low-dose teduglutide produced support reduction responses more often than standard care.JPEN. Journal of parenteral and enteral nutrition, 2020

Teduglutide studies on side effects

67 results · people 67 · animals 0 · lab 0

Top 5 of 67 results

In patients with short bowel syndrome, serious adverse events were similar with teduglutide and placebo.Gut, 2011
In patients with short bowel syndrome, teduglutide did not change digestive adverse event probability compared with placebo in adjusted analysis.JPEN. Journal of parenteral and enteral nutrition, 2017
In adults receiving teduglutide, colon polyps occurred in 18% after exposure and 12% at baseline, with different denominators.Clinical nutrition, 2020
In patients with short bowel syndrome, 28% reported catheter sepsis during the teduglutide extension study.Clinical and translational gastroenterology, 2016
In patients with short bowel syndrome, 25% reported decreased weight during the teduglutide extension study.Clinical and translational gastroenterology, 2016

Teduglutide studies on stomach and gut

93 results · people 36 · animals 57 · lab 0

Top 5 of 93 results

In SBS-IF patients, teduglutide produced more parenteral support volume responders than placebo.Gastroenterology, 2012
Five of six adults had the defined fistula-volume response with teduglutide, but not with standard care.Clinical nutrition ESPEN, 2022
In healthy subjects, acetaminophen exposure to the last measurement did not differ significantly between teduglutide and placebo.BMC gastroenterology, 2014
In SBS patients in CL0600-004, lower-dose teduglutide increased citrulline more than placebo at Week 24.Clinical and translational gastroenterology, 2015
In all studied SBS-IF subgroups, teduglutide increased blood citrulline numerically more than placebo.Clinical nutrition, 2020

Teduglutide studies on blood levels and clearance

17 results · people 13 · animals 4 · lab 0

Top 3 of 17 results

In subjects with end-stage renal disease, teduglutide exposure was approximately 2.59-fold higher than in healthy subjects.European journal of clinical pharmacology, 2013
In healthy subjects, teduglutide exposure was similar on days 1 and 8, suggesting little accumulation.Journal of clinical pharmacology, 2008
Teduglutide was absorbed quickly in Japanese adults with SBS-IF.Surgery today, 2023

Teduglutide studies on daily life and fitness

13 results · people 13 · animals 0 · lab 0

Top 3 of 13 results

In SBS-IF patients, teduglutide did not significantly improve the total quality-of-life score compared with placebo.Clinical nutrition, 2013
In adults with SBS, teduglutide numerically improved quality-of-life scores versus placebo, without statistical significance.JPEN. Journal of parenteral and enteral nutrition, 2020
Children with SBS-IF receiving teduglutide had a mean quality-of-life score of 75.0.Journal of pediatric gastroenterology and nutrition, 2026

Teduglutide studies on overall treatment results

5 results · people 5 · animals 0 · lab 0

Top 3 of 5 results

In patients with Crohn's disease, clinical response rates were numerically higher with teduglutide than placebo.Inflammatory bowel diseases, 2010
In Crohn's disease, response was 44% with the highest teduglutide dose versus 32% with placebo.Inflammatory bowel diseases, 2010
In patients with Crohn's disease, remission rates were numerically higher with teduglutide than placebo.Inflammatory bowel diseases, 2010

Teduglutide studies on heart and blood vessels

4 results · people 4 · animals 0 · lab 0

4 results

In healthy volunteers, QTcF curves after both teduglutide doses were almost identical to placebo curves.Clinical pharmacology in drug development, 2012
In healthy men, teduglutide rapidly increased blood flow to the intestine.Diabetes, obesity & metabolism, 2019
In healthy volunteers, the upper confidence bound for QTcF change after teduglutide 5 mg was 3.0 ms.Clinical pharmacology in drug development, 2012
In healthy volunteers, the upper confidence bound for QTcF change after teduglutide 20 mg was 4.5 ms.Clinical pharmacology in drug development, 2012

Teduglutide studies on liver

11 results · people 3 · animals 8 · lab 0

Top 3 of 11 results

In adults with SBS-IF, teduglutide reduced AST more than placebo at week 24.Nutrition in clinical practice, 2024
In adults with SBS-IF, teduglutide reduced ALT more than placebo at week 24.Nutrition in clinical practice, 2024
In adults with SBS-IF, teduglutide reduced bilirubin more than placebo at week 24.Nutrition in clinical practice, 2024

Teduglutide studies on cholesterol and blood fats

3 results · people 3 · animals 0 · lab 0

3 results

In healthy men, teduglutide rapidly increased blood triglycerides.Diabetes, obesity & metabolism, 2019
In healthy men, teduglutide rapidly increased triglycerides in triglyceride-rich particles.Diabetes, obesity & metabolism, 2019
In healthy men, teduglutide increased triglycerides most strongly in chylomicrons.Diabetes, obesity & metabolism, 2019

Teduglutide studies on weight and appetite

9 results · people 2 · animals 7 · lab 0

Top 5 of 9 results

In patients with short bowel syndrome, weight, body mass index and serum albumin remained stable during teduglutide treatment.Clinical and translational gastroenterology, 2016
In patients with short bowel syndrome, teduglutide increased lean body mass versus placebo.Gut, 2011
In mice, food intake was higher with teduglutide alone than with GUB09-123.Physiology & behavior, 2018
In piglets with jejunostomy, teduglutide increased body weight more than placebo, with similar increments across the tested doses.Journal of pediatric gastroenterology and nutrition, 2014
In mice, acute teduglutide treatment in the brain reduced food intake.British journal of pharmacology, 2021

Teduglutide studies on growth hormone and growth

2 results · people 2 · animals 0 · lab 0

2 results

In children under 10 kg with short bowel syndrome, weight-for-age scores increased from baseline after teduglutide.Pediatrics international, 2026
In children under 10 kg with short bowel syndrome, height or length-for-age scores increased from baseline after teduglutide.Pediatrics international, 2026

Teduglutide studies on salt, water and minerals

2 results · people 2 · animals 0 · lab 0

2 results

In adults with short bowel syndrome, teduglutide numerically reduced stool weight versus placebo, without statistical significance.JPEN. Journal of parenteral and enteral nutrition, 2016
In adults with short bowel syndrome, teduglutide numerically increased urine volume versus placebo, without statistical significance.JPEN. Journal of parenteral and enteral nutrition, 2016

Teduglutide studies on immune system and inflammation

11 results · people 1 · animals 2 · lab 8

Top 5 of 11 results

In Japanese adults with SBS-IF, antibodies against teduglutide declined during long-term treatment.Surgery today, 2023
In mice, chronic peripheral teduglutide reduced inflammation in visceral fat.British journal of pharmacology, 2021
In mice with GVHD, cell regeneration after teduglutide enhanced antimicrobial peptide production.Blood, 2020
In lab tests, teduglutide reduced LPS-induced macrophage-dependent IL1B expression in human islets.Frontiers in endocrinology, 2021
In lab tests, teduglutide reduced LPS-induced macrophage-dependent IL10 expression in human islets.Frontiers in endocrinology, 2021

Teduglutide studies on use, access and costs

1 result · people 1 · animals 0 · lab 0

1 result

Adults with low-output intestinal fistulas completed 98% of daily teduglutide injections.Clinical nutrition ESPEN, 2022

Teduglutide studies on cells, genes and aging

9 results · people 0 · animals 9 · lab 0

Top 5 of 9 results

In mice, teduglutide pretreatment reduced lipid oxidation versus injury without pretreatment.Molecular and cellular biochemistry, 2011
In mice, teduglutide pretreatment reduced cell death versus injury without pretreatment.Molecular and cellular biochemistry, 2011
In mice with lung injury, teduglutide pretreatment reduced cell death versus injury without pretreatment.Peptides, 2012
In mice with lung injury, teduglutide pretreatment reduced lipid oxidation versus injury without pretreatment.Peptides, 2012
In mice, teduglutide pretreatment reduced glutathione levels versus injury without pretreatment.Molecular and cellular biochemistry, 2011

Teduglutide studies on brain and nerves

6 results · people 0 · animals 6 · lab 0

Top 3 of 6 results

In obese mice, teduglutide reduced inflammation and stress marker increases compared with untreated HFD mice.Neurobiology of disease, 2019
In obese mice, teduglutide reduced brain reactive oxygen species compared with untreated HFD mice.Neurobiology of disease, 2019
In obese mice, brain GFAP increases were smaller with teduglutide than in untreated HFD mice.Neurobiology of disease, 2019

Teduglutide studies on blood sugar

7 results · people 0 · animals 2 · lab 5

Top 5 of 7 results

In mice, glucose tolerance was worse with teduglutide alone than with GUB09-123.Physiology & behavior, 2018
In lab tests, teduglutide did not change acute insulin release from human islets.Frontiers in endocrinology, 2021
In mice, chronic peripheral teduglutide improved glucose tolerance independently of body weight.British journal of pharmacology, 2021
In lab tests, teduglutide did not change glucose-stimulated insulin release from human islets.Frontiers in endocrinology, 2021
In lab tests, teduglutide did not change insulin content in human islets.Frontiers in endocrinology, 2021

Teduglutide studies on cancer

1 result · people 0 · animals 1 · lab 0

1 result

In mice, teduglutide did not compromise graft-versus-leukemia effects.Blood, 2020

Teduglutide studies on hormones

1 result · people 0 · animals 1 · lab 0

1 result

In wild-type mice with short bowel syndrome, teduglutide lowered blood aldosterone versus vehicle.Digestive diseases and sciences, 2020

Teduglutide studies on lungs and breathing

1 result · people 0 · animals 1 · lab 0

1 result

In mice with lung injury, teduglutide pretreatment reduced structural damage versus injury without pretreatment.Peptides, 2012

Teduglutide studies on receptors and cell signals

12 results · people 0 · animals 0 · lab 12

Top 5 of 12 results

In cells, teduglutide increased Caco-2 cell numbers by 10% compared with untreated controls.JAMA surgery, 2013
In lab tests, teduglutide had GLP-2 receptor potency comparable to native hGLP-2.The Journal of pharmacology and experimental therapeutics, 2020
In cells, teduglutide acted as a growth-promoting signal in human fat cells.British journal of pharmacology, 2021
In cells, teduglutide increased bromodeoxyuridine-positive Caco-2 cells compared with untreated controls.JAMA surgery, 2013
In lab tests, teduglutide had GLP-2 receptor selectivity comparable to native hGLP-2.The Journal of pharmacology and experimental therapeutics, 2020

Trials and papers

Teduglutide trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

46 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (25 of 46)

25 of 46 trials

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

20052010201520202025

Ph 3
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome
NCT00081458
25 May 2004 to 6 Jul 2007
Ph 3
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)
NCT00172185
10 Jan 2005 to 24 Jan 2008
Ph 3
STEPS
NCT00798967
25 Nov 2008 to 25 Jan 2011
Ph 3
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
NCT00930644
21 Sept 2009 to 24 Jan 2013
Ph 3
STEPS3
NCT01560403
21 May 2012 to 23 Jul 2013
Ph 3
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
NCT01952080
14 Nov 2013 to 9 Jan 2015
Ph 4
Short Bowel Syndrome and Teduglutide Versus Placebo
NCT02099084
Jan 2014 to Mar 2015
Ph 3
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)
NCT02340819
18 Dec 2014 to 5 Nov 2018
Ph 3
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
NCT02682381
23 Jun 2016 to 18 Aug 2017
Ph 3
Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study
NCT02949362
9 Dec 2016 to 14 Jul 2020

Browse all 46 matching trials in the list below

25 trials · 1 ongoing · 22 completed · 1 stopped early · 17 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT04344717

Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition

Universitaire Ziekenhuizen KU Leuvenn = 7020 Dec 2020 to 30 Sept 2025

Short Bowel Syndrome · Anticoagulation

Trial page ClinicalTrials.govUpdated 15 Oct 2026

CompletedPhase 4NCT03562130

Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients

Assistance Publique - Hôpitaux de Parisn = 252 Jul 2018 to 13 Jul 2020

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 11 Sept 2025

CompletedPhase 4Results postedNCT02099084

Short Bowel Syndrome and Teduglutide Versus Placebo

Mayo Clinicn = 8Jan 2014 to Mar 2015

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 22 Feb 2016

Active, not recruitingPhase 3NCT06973304

A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

Takedan = 1326 Jun 2025 to est. 28 Jul 2027

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 8 Sept 2026

CompletedPhase 3Results postedNCT02954458

Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)

Shiren = 619 Jan 2017 to 5 Nov 2020

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 28 Mar 2025

CompletedPhase 3Results postedNCT02949362

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

Shiren = 299 Dec 2016 to 14 Jul 2020

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 19 Mar 2025

CompletedPhase 3Results postedNCT05027308

A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older

Takedan = 34 Jan 2022 to 27 Sept 2023

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 16 May 2024

CompletedPhase 3Results postedNCT03596164

An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004

Takedan = 119 Jul 2018 to 13 Jan 2022

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 15 Mar 2023

WithdrawnPhase 3NCT03953170

Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)n = 02 Jun 2022 to 29 Dec 2022

Ileostomy - Stoma

Trial page ClinicalTrials.govUpdated 23 Feb 2023

CompletedPhase 2/3NCT03422666

Plasma Lipoprotein Response to Glucagon-like Peptide-2

University Health Network, Toronton = 1021 Sept 2018 to 1 Dec 2021

Hyperlipidemias

Trial page ClinicalTrials.govUpdated 14 Jun 2022

CompletedPhase 2/3NCT03442972

Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids

University Health Network, Toronton = 2117 Jan 2019 to 1 Dec 2021

Hyperlipidemias

Trial page ClinicalTrials.govUpdated 25 May 2022

CompletedPhase 3Results postedNCT03268811

A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302

Shiren = 923 Aug 2017 to 2 Nov 2021

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 24 May 2022

CompletedPhase 3Results postedNCT02980666

Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support

Shiren = 1013 Jan 2017 to 21 Jan 2020

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 2 Feb 2022

CompletedPhase 3Results postedNCT00930644

Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)

Shiren = 8821 Sept 2009 to 24 Jan 2013

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 11 Jun 2021

CompletedPhase 3Results postedNCT01560403

A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021

Shiren = 1421 May 2012 to 23 Jul 2013

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 10 Jun 2021

CompletedPhase 3Results postedNCT00081458

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

Shiren = 8425 May 2004 to 6 Jul 2007

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 9 Jun 2021

CompletedPhase 3Results postedNCT01952080

A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome

Shiren = 4214 Nov 2013 to 9 Jan 2015

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 9 Jun 2021

CompletedPhase 3Results postedNCT02340819

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)

Shiren = 1118 Dec 2014 to 5 Nov 2018

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 9 Jun 2021

CompletedPhase 3Results postedNCT02682381

Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition

Shiren = 5923 Jun 2016 to 18 Aug 2017

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 9 Jun 2021

CompletedPhase 3Results postedNCT00798967

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

Shiren = 8625 Nov 2008 to 25 Jan 2011

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 3 Jun 2021

CompletedPhase 3Results postedNCT00172185

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

Shiren = 6510 Jan 2005 to 24 Jan 2008

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 2 Jun 2021

CompletedPhase 3Results postedNCT03571516

Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome

Shiren = 1031 Aug 2018 to 24 Sept 2020

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 11 May 2021

Status unknownPhase 2/3NCT03860688

Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins

University Health Network, Toronton = 151 May 2019 to est. May 2022

Hyperlipidemias

Trial page ClinicalTrials.govUpdated 29 Apr 2021

CompletedPhase 3Results postedNCT03663582

Study of Teduglutide in Japanese Participants With Short Bowel Syndrome

Shiren = 76 Jul 2018 to 6 Aug 2019

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 4 Aug 2020

CompletedPhase 2/3NCT03534661

L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release

University Health Network, Toronton = 1027 Sept 2017 to 20 Mar 2019

Hyperlipidemias

Trial page ClinicalTrials.govUpdated 27 Mar 2020

4 more mention it but do not test it. They are not trials of Teduglutide: they only measure it (a blood level or an eligibility term) or name it in their text.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

256 studies match. Retracted studies are left out.

Showing 25 of 256 studiesquery qry_da91379b92424165e5511e68

Studies with results

54 studies in all, 19 on this page

Non-randomized trial · 2012

5 results

Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.

Jeppesen et al. 2012Gastroenterologyn = 86cited by 348

PMID 22982184DOI 10.1053/j.gastro.2012.09.007PUB-22982184

Rights unknown5 results where Teduglutide was given

Source link See results (5)

Randomized controlled trial · 2011

8 results

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.

Jeppesen et al. 2011Gutn = 83cited by 323

PMID 21317170PMC3112364DOI 10.1136/gut.2010.218271PUB-21317170

Free to read · publisher termsCC BY-NC8 results where Teduglutide was given

Read at source See results (8)

Non-randomized trial · 2016

11 results

Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome.

Schwartz et al. 2016Clinical and translational gastroenterologyn = 88cited by 157

PMID 26844839PMC4817413DOI 10.1038/ctg.2015.69PUB-26844839

Free to read · publisher termsCC BY-NC-ND11 results where Teduglutide was given

Read at source See results (11)

Non-randomized trial · 2017

13 results

Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.

Carter et al. 2017The Journal of pediatricscited by 135

PMID 27855998DOI 10.1016/j.jpeds.2016.10.027PUB-27855998

Full text at the publisher13 results where Teduglutide was given

Publisher page See results (13)

Animal study (in vivo) · mouse · 2018

1 result

Increased gut permeability in cancer cachexia: mechanisms and clinical relevance.

Bindels et al. 2018Oncotargetcited by 130

PMID 29719601PMC5915068DOI 10.18632/oncotarget.24804PUB-29719601

CC BY1 result where Teduglutide was given

Download PDF See results (1)

Non-randomized trial · 2013

11 results

Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.

O'Keefe et al. 2013Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Associationn = 52cited by 122

PMID 23333663DOI 10.1016/j.cgh.2012.12.029PUB-23333663

Full text at the publisher11 results where Teduglutide was given

Publisher page See results (11)

Randomized controlled trial · 2010

7 results

Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.

Buchman et al. 2010Inflammatory bowel diseasescited by 109

PMID 19821509DOI 10.1002/ibd.21117PUB-19821509

Full text at the publisher7 results where Teduglutide was given

Publisher page See results (7)

Non-randomized trial · 2018

4 results

Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.

Jeppesen et al. 2018Gastroenterologycited by 102

PMID 29174926DOI 10.1053/j.gastro.2017.11.023PUB-29174926

Free to read · publisher termsCC BY-NC-ND4 results where Teduglutide was given

Read at source See results (4)

Animal study (in vivo) · mouse · 2020

7 results

Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans.

Norona et al. 2020Bloodcited by 99

PMID 32542357PMC7498363DOI 10.1182/blood.2020005957PUB-32542357

Rights unknown7 results where Teduglutide was given

Source link See results (7)

Non-randomized trial · 2020

19 results

Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.

Kocoshis et al. 2020JPEN. Journal of parenteral and enteral nutritionn = 59cited by 98

PMID 31495952PMC7318247DOI 10.1002/jpen.1690PUB-31495952

Free to read · publisher termsCC BY-NC19 results where Teduglutide was given

Read at source See results (19)

Randomized controlled trial · 2013

6 results

Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.

Jeppesen et al. 2013Clinical nutrition (Edinburgh, Scotland)n = 86cited by 79

PMID 23587733DOI 10.1016/j.clnu.2013.03.016PUB-23587733

Full text at the publisher6 results where Teduglutide was given

Publisher page See results (6)

Observational study · 2017

2 results

Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.

Iyer et al. 2017JPEN. Journal of parenteral and enteral nutritionn = 134cited by 68

PMID 27875291PMC5639959DOI 10.1177/0148607116680791PUB-27875291

Free to read · publisher termsCC BY-NC2 results where Teduglutide was given

Read at source See results (2)

Animal study (in vivo) · mouse · 2004

7 results

Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage.

Booth et al. 2004Cell proliferationcited by 67

PMID 15548172PMC6495530DOI 10.1111/j.1365-2184.2004.00320.xPUB-15548172

Rights unknown7 results where Teduglutide was given

Source link See results (7)

Non-randomized trial · 2018

9 results

Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study.

Seidner et al. 2018Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutritionn = 14cited by 66

PMID 29761915DOI 10.1002/ncp.10092PUB-29761915

Full text at the publisher9 results where Teduglutide was given

Publisher page See results (9)

Non-randomized trial · 2008

9 results

Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects.

Marier et al. 2008Journal of clinical pharmacologycited by 65

PMID 18974283DOI 10.1177/0091270008320605PUB-18974283

Full text at the publisher9 results where Teduglutide was given

Publisher page See results (9)

Animal study (in vivo) · rat · 2020

2 results

Lipopolysaccharides transport during fat absorption in rodent small intestine.

Akiba et al. 2020American journal of physiology. Gastrointestinal and liver physiologycited by 53

PMID 32390462PMC7311662DOI 10.1152/ajpgi.00079.2020PUB-32390462

Rights unknown2 results where Teduglutide was given

Source link See results (2)

Non-randomized trial · 2013

4 results

Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome.

Tappenden et al. 2013Journal of clinical gastroenterologycited by 51

PMID 23426461DOI 10.1097/mcg.0b013e3182828f57PUB-23426461

Full text at the publisher4 results where Teduglutide was given

Publisher page See results (4)

Animal study (in vivo) · rat · 2020

15 results

Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.

Hargrove et al. 2020The Journal of pharmacology and experimental therapeuticscited by 51

PMID 32075870DOI 10.1124/jpet.119.262238PUB-32075870

Rights unknown5 results where Teduglutide was given

Source link See results (15)

Randomized controlled trial · 2020

4 results

Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure.

Chen et al. 2020JPEN. Journal of parenteral and enteral nutritionn = 86cited by 48

PMID 31006876PMC7004164DOI 10.1002/jpen.1588PUB-31006876

Free to read · publisher termsCC BY-NC4 results where Teduglutide was given

Read at source See results (4)

More studies

195 studies in all, 6 on this page

PubMed tag: Clinical Trial, Multicenter Study · 2005

Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.

Jeppesen et al. 2005Gutcited by 353

PMID 16099790PMC1774653DOI 10.1136/gut.2004.061440PUB-16099790

Rights unknown

Source link

PubMed tag: Observational Study, Multicenter Study · 2020

Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study.

Joly et al. 2020Clinical nutrition (Edinburgh, Scotland)cited by 65

PMID 31932048DOI 10.1016/j.clnu.2019.12.019PUB-31932048

Rights unknown

Source link

PubMed tag: Historical Article · 2015

Deciphering metabolic messages from the gut drives therapeutic innovation: the 2014 Banting Lecture.

Drucker et al. 2015Diabetescited by 61

PMID 25614665DOI 10.2337/db14-1514PUB-25614665

Rights unknown

Source link

Indexing hint: Animal study · 2018

Stapled, Long-Acting Glucagon-like Peptide 2 Analog with Efficacy in Dextran Sodium Sulfate Induced Mouse Colitis Models.

Yang et al. 2018Journal of medicinal chemistrycited by 54

PMID 29528634DOI 10.1021/acs.jmedchem.7b00768PUB-29528634

Full text at the publisher

Publisher page

PubMed tag: none · 2019

Experience with teduglutide treatment for short bowel syndrome in clinical practice.

Pevny et al. 2019Clinical nutrition (Edinburgh, Scotland)cited by 52

PMID 30145039DOI 10.1016/j.clnu.2018.07.030PUB-30145039

Full text at the publisher

Publisher page

PubMed tag: none · 2012

Corrected

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.

Alters et al. 2012PloS onecited by 47

PMID 23189208PMC3506575DOI 10.1371/journal.pone.0050630PUB-23189208

CC BY

Download PDF Read the notice

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Teduglutide studies: 54 papers with results

Page 1 of 2

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.
Jeppesen PB · Gut · 2011
Randomized controlled trial · 8 results
A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.
Berg JK · BMC gastroenterology · 2014
Randomized controlled trial · 7 results
Teduglutide for the treatment of low-output enterocutaneous fistula - A pilot randomized controlled study.
Yeh DD · Clinical nutrition ESPEN · 2022
Randomized controlled trial · 4 results
Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.
Buchman AL · Inflammatory bowel diseases · 2010
Randomized controlled trial · 7 results
Malnutrition enteropathy in Zambian and Zimbabwean children with severe acute malnutrition: A multi-arm randomized phase II trial.
Chandwe K · Nature communications · 2024
Randomized controlled trial · 1 result
Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis.
Micic D · Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2024
Randomized controlled trial · 3 results
Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide.
Fujioka K · JPEN. Journal of parenteral and enteral nutrition · 2017
Randomized controlled trial · 2 results
Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
Jeppesen PB · Clinical nutrition (Edinburgh, Scotland) · 2013
Randomized controlled trial · 6 results
Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure.
Chen K · JPEN. Journal of parenteral and enteral nutrition · 2020
Randomized controlled trial · 4 results
Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome.
Chen KS · Therapeutics and clinical risk management · 2018
Randomized controlled trial · 5 results
A Thorough QT Study of Teduglutide in Healthy Subjects.
Hartmann M · Clinical pharmacology in drug development · 2012
Randomized controlled trial · 5 results
Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials.
Seidner DL · Clinical and translational gastroenterology · 2015
Randomized controlled trial · 5 results
Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study.
Jeppesen PB · Clinical nutrition (Edinburgh, Scotland) · 2020
Randomized controlled trial · 1 result
Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure.
Fifi A · Journal of pediatric gastroenterology and nutrition · 2023
Non-randomized trial · 3 results
Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
Jeppesen PB · Gastroenterology · 2012
Non-randomized trial · 5 results
Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.
Kocoshis SA · JPEN. Journal of parenteral and enteral nutrition · 2020
Non-randomized trial · 19 results
Pharmacokinetics of teduglutide in subjects with renal impairment.
Nave R · European journal of clinical pharmacology · 2013
Non-randomized trial · 7 results
Safety Findings in Pediatric Patients During Long-Term Treatment With Teduglutide for Short-Bowel Syndrome-Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies.
Hill S · JPEN. Journal of parenteral and enteral nutrition · 2021
Non-randomized trial · 14 results
Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome.
Schwartz LK · Clinical and translational gastroenterology · 2016
Non-randomized trial · 11 results
Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure.
Wales PW · Journal of pediatric gastroenterology and nutrition · 2024
Non-randomized trial · 5 results
Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide.
Wendel D · Journal of pediatric gastroenterology and nutrition · 2026
Non-randomized trial · 4 results
Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.
O'Keefe SJ · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2013
Non-randomized trial · 11 results
Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series.
Armstrong D · Clinical nutrition (Edinburgh, Scotland) · 2020
Non-randomized trial · 5 results
Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials.
Seidner DL · JPEN. Journal of parenteral and enteral nutrition · 2020
Non-randomized trial · 7 results
Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support.
Chen K · Clinical nutrition ESPEN · 2021
Non-randomized trial · 12 results
Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension.
Nakamura S · Surgery today · 2023
Non-randomized trial · 8 results
Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study.
Seidner DL · Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2018
Non-randomized trial · 9 results
Glucagon-like peptide-2 mobilizes lipids from the intestine by a systemic nitric oxide-independent mechanism.
Xiao C · Diabetes, obesity & metabolism · 2019
Non-randomized trial · 4 results
Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition.
Iturrino J · JPEN. Journal of parenteral and enteral nutrition · 2016
Non-randomized trial · 8 results
Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study.
Masumoto K · Pediatrics international : official journal of the Japan Pediatric Society · 2026
Non-randomized trial · 8 results
Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.
Carter BA · The Journal of pediatrics · 2017
Non-randomized trial · 13 results
Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.
Jeppesen PB · Gastroenterology · 2018
Non-randomized trial · 4 results
Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects.
Marier JF · Journal of clinical pharmacology · 2008
Non-randomized trial · 9 results
Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome.
Tappenden KA · Journal of clinical gastroenterology · 2013
Non-randomized trial · 4 results
Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials.
Pape UF · Therapeutic advances in gastroenterology · 2020
Non-randomized trial · 9 results
Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.
Iyer KR · JPEN. Journal of parenteral and enteral nutrition · 2017
Observational study · 2 results
Comparing the Intestinotrophic Effects of 2 Glucagon-Like Peptide-2 Analogues in the Treatment of Short-Bowel Syndrome in Neonatal Piglets.
Pauline ML · JPEN. Journal of parenteral and enteral nutrition · 2021
Animal study (in vivo) · pig · 19 results
Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.
Thymann T · Journal of pediatric gastroenterology and nutrition · 2014
Animal study (in vivo) · pig · 4 results
Increased gut permeability in cancer cachexia: mechanisms and clinical relevance.
Bindels LB · Oncotarget · 2018
Animal study (in vivo) · mouse · 1 result
Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans.
Norona J · Blood · 2020
Animal study (in vivo) · mouse · 7 results
Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage.
Booth C · Cell proliferation · 2004
Animal study (in vivo) · mouse · 7 results
Lipopolysaccharides transport during fat absorption in rodent small intestine.
Akiba Y · American journal of physiology. Gastrointestinal and liver physiology · 2020
Animal study (in vivo) · rat · 2 results
Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.
Hargrove DM · The Journal of pharmacology and experimental therapeutics · 2020
Animal study (in vivo) · rat · 15 results
The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant-antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-alpha/actinomycin D.
Arda-Pirincci P · Molecular and cellular biochemistry · 2011
Animal study (in vivo) · mouse · 9 results
Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
Wismann P · Physiology & behavior · 2018
Animal study (in vivo) · mouse · 5 results
Glucagon-like peptide-2 reduces the obesity-associated inflammation in the brain.
Nuzzo D · Neurobiology of disease · 2019
Animal study (in vivo) · mouse · 6 results
GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/- Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR Signaling.
Fuchs CD · Cellular and molecular gastroenterology and hepatology · 2023
Animal study (in vivo) · mouse · 8 results
GLP-2 Acutely Prevents Endotoxin-Related Increased Intestinal Paracellular Permeability in Rats.
Maruta K · Digestive diseases and sciences · 2020
Animal study (in vivo) · rat · 1 result
Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency.
Reiner J · Digestive diseases and sciences · 2020
Animal study (in vivo) · mouse · 7 results
Teduglutide-Stimulated Intestinal Adaptation Is Complemented and Synergistically Enhanced by Partial Enteral Nutrition in a Neonatal Piglet Model of Short Bowel Syndrome.
Naberhuis JK · JPEN. Journal of parenteral and enteral nutrition · 2017
Animal study (in vivo) · pig · 17 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	Gattex	27 Oct 2026	dailymed.nlm.nih.gov (opens in a new tab)
EU	EMA	Revestive	27 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Not listed as banned by WADA Teduglutide, GATTEX, and Revestive are not named in the 2026 list.	2026 List	wada-ama.org (opens in a new tab)

Safety outcomes

73 safety results for Teduglutide.

Human evidence· 73

In patients with short bowel syndrome, teduglutide treatment did not affect GI adverse event probability in logistic regression analysis.
Randomized controlled trialn = 136
In patients with short bowel syndrome, serious adverse events were distributed similarly between teduglutide groups and placebo.
Randomized controlled trialn = 83
In healthy volunteers, QTcF curves after both teduglutide doses were almost superposable with placebo curves.
Randomized controlled trialn = 72
In Crohn's disease, adverse events did not differ between teduglutide groups and placebo.
Randomized controlled trialn not reported
All 89 children with SBS-IF receiving teduglutide had adverse events.
Non-randomized trialn = 89
Vomiting occurred in 51.7% of children receiving teduglutide.
Non-randomized trialn = 89
Vomiting incidence
51.7%
pediatric patients treated with teduglutide
In patients with short bowel syndrome, 34% reported abdominal pain during the teduglutide extension study.
Non-randomized trialn = 88
Patients with abdominal pain
34%
treatment-emergent adverse event, STEPS-2 extension
In children with SBS-IF, most TEAEs were moderate or severe in intensity in the any-teduglutide group and in the seven patients who did not receive teduglutide in either the parent or LTE studies.
Non-randomized trialn = 78

The top 24 of 73 results.

Doses studied · 46

The doses that these studies used. They are not recommendations.

0.05 mg/kg/dayHuman
Species
human
Route
subcutaneous
Duration
24 weeks
Design
Randomized controlled trial · n = 51
0.10 mg/kg/dayHuman
Species
human
Route
subcutaneous
Duration
24 weeks
Design
Randomized controlled trial · n = 48
4 mg once dailyHuman
Species
human
Route
subcutaneous
Duration
10 days
Design
Randomized controlled trial · n = 36
0.05, 0.10, or 0.20 mg/kg dailyHuman
Species
human
Route
subcutaneous
Duration
8 weeks
Design
Randomized controlled trial
0.2 mg/kg/dHuman
Species
human
Route
subcutaneous
Duration
Not reported
Design
Randomized controlled trial
0.05 or 0.10 mg/kg/dayHuman
Species
human
Route
subcutaneous
Duration
24 weeks
Design
Randomized controlled trial · n = 168

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
0.05 mg/kg/day	Human	human	subcutaneous	24 weeks	Randomized controlled trial · n = 51
0.10 mg/kg/day	Human	human	subcutaneous	24 weeks	Randomized controlled trial · n = 48
4 mg once daily	Human	human	subcutaneous	10 days	Randomized controlled trial · n = 36
0.05, 0.10, or 0.20 mg/kg daily	Human	human	subcutaneous	8 weeks	Randomized controlled trial
0.2 mg/kg/d	Human	human	subcutaneous	Not reported	Randomized controlled trial
0.05 or 0.10 mg/kg/day	Human	human	subcutaneous	24 weeks	Randomized controlled trial · n = 168

6 of 46 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000171
Peptide version: 2
Peptide hash: 88d35d480ed42b7e…
Data version: 308560

Latest changes

28 Oct 2026UpdatedData version 304203
27 Oct 2026CreatedData version 256782

For developers

curl -s https://pepbank.io/v1/briefs/teduglutide

Evidence summary for Teduglutide: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Intensive care and hospital outcomesGastrointestinal	Human: 85 results from 14 studies: 14 increase, 47 decrease, 3 no significant change, 21 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	85
Adverse eventsWhole body	Human: 50 results from 19 studies: 1 increase, 1 decrease, 2 no significant change, 46 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	50
Gastrointestinal adverse eventsGastrointestinal	Human: 17 results from 7 studies: 3 increase, 5 decrease, 2 no significant change, 7 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	17
PharmacokineticsPharmacology	Human: 13 results from 3 studies: 8 increase, 1 no significant change, 4 not reported. Strongest design: Non-randomized trial	Animal: 4 results from 2 studies: 1 mixed, 3 not reported. Strongest design: Animal study (in vivo)	No results	No results	17
Quality of lifeWhole body	Human: 13 results from 3 studies: 2 increase, 3 decrease, 3 no significant change, 5 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	13
Parenteral supportGastrointestinal	Human: 10 results from 3 studies: 2 increase, 3 decrease, 5 not reported. Strongest design: Non-randomized trial	No results	No results	No results	10
Gastrointestinal protectionGastrointestinal	Human: 6 results from 4 studies: 3 increase, 2 decrease, 1 not reported. Strongest design: Randomized controlled trial	Animal: 41 results from 9 studies: 26 increase, 9 decrease, 1 no significant change, 5 not reported. Strongest design: Animal study (in vivo)	No results	No results	47
Gastrointestinal motilityGastrointestinal	Human: 6 results from 2 studies: 1 decrease, 5 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	6
Intestinal adaptationGastrointestinal	Human: 5 results from 2 studies: 4 increase, 1 mixed. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 2 increase. Strongest design: Animal study (in vivo)	No results	No results	7
Disease ActivityGastrointestinal	Human: 5 results from 1 study: 4 increase, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	5
Liver fat and liver functionLiver	Human: 3 results from 1 study: 3 decrease. Strongest design: Randomized controlled trial	Animal: 8 results from 1 study: 3 increase, 5 decrease. Strongest design: Animal study (in vivo)	No results	No results	11
Heart functionCardiovascular	Human: 3 results from 1 study: 3 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	3

Outcome group	Human	Animal	Lab	Computer model	Total
Intensive care and hospital outcomesGastrointestinal	Human: 85 results from 14 studies: 14 increase, 47 decrease, 3 no significant change, 21 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	85
Adverse eventsWhole body	Human: 50 results from 19 studies: 1 increase, 1 decrease, 2 no significant change, 46 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	50
Gastrointestinal adverse eventsGastrointestinal	Human: 17 results from 7 studies: 3 increase, 5 decrease, 2 no significant change, 7 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	17
PharmacokineticsPharmacology	Human: 13 results from 3 studies: 8 increase, 1 no significant change, 4 not reported. Strongest design: Non-randomized trial	Animal: 4 results from 2 studies: 1 mixed, 3 not reported. Strongest design: Animal study (in vivo)	No results	No results	17
Quality of lifeWhole body	Human: 13 results from 3 studies: 2 increase, 3 decrease, 3 no significant change, 5 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	13
Parenteral supportGastrointestinal	Human: 10 results from 3 studies: 2 increase, 3 decrease, 5 not reported. Strongest design: Non-randomized trial	No results	No results	No results	10
Gastrointestinal protectionGastrointestinal	Human: 6 results from 4 studies: 3 increase, 2 decrease, 1 not reported. Strongest design: Randomized controlled trial	Animal: 41 results from 9 studies: 26 increase, 9 decrease, 1 no significant change, 5 not reported. Strongest design: Animal study (in vivo)	No results	No results	47
Gastrointestinal motilityGastrointestinal	Human: 6 results from 2 studies: 1 decrease, 5 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	6
Intestinal adaptationGastrointestinal	Human: 5 results from 2 studies: 4 increase, 1 mixed. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 2 increase. Strongest design: Animal study (in vivo)	No results	No results	7
Disease ActivityGastrointestinal	Human: 5 results from 1 study: 4 increase, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	5
Liver fat and liver functionLiver	Human: 3 results from 1 study: 3 decrease. Strongest design: Randomized controlled trial	Animal: 8 results from 1 study: 3 increase, 5 decrease. Strongest design: Animal study (in vivo)	No results	No results	11
Heart functionCardiovascular	Human: 3 results from 1 study: 3 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	3